{
  "chapter": "Anticancer Drugs-Previous Year Questions",
  "questions": [
    {
      "q_no": 1,
      "question": "Which corticosteroid is recommended for promoting the maturation of fetal lungs in preterm labor?",
      "options": {
        "A": "Hydrocortisone",
        "B": "Triamcinolone",
        "C": "Methylprednisolone",
        "D": "Betamethasone"
      },
      "correct_answer": "D",
      "explanation": "of fetal lung maturation in preterm labor. Betamethasone belongs to the class of glucocorticoids and has potent anti-inflammatory and immunosuppressive properties. It is commonly used in obstetrics to enhance fetal lung maturity when preterm delivery is anticipated. Administering betamethasone to the pregnant woman helps promote the production of surfactant in the fetal lungs, which is crucial for the proper functioning of the lungs and prevention of respiratory distress syndrome (RDS) in preterm infants. Incorrect Options: Option A: Hydrocortisone is a corticosteroid that has a wide range of uses, but it is not specifically indicated for fetal lung maturation in preterm labor. Option B: Triamcinolone, another corticosteroid, is primarily used for its anti-inflammatory properties and is not the preferred choice for fetal lung maturation. Option C: Methylprednisolone- Methylprednisolone is a corticosteroid that is used for various medical conditions, including inflammatory and autoimmune disorders. However, it is not the corticosteroid of choice for the stimulation of fetal lung maturation in preterm labor.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 2,
      "question": "Please match the drugs with their respective targets of action. Trastuzumab BCR-ABL tyrosine kinase Infliximab 2. mTOR Sirolimus 3. TNF alpha Imatinib 4. HER2/neu",
      "options": {
        "A": "A-2, B-3, C-1, D-4",
        "B": "A-4, B-3, C-1, D-2",
        "C": "A-3, B-4, C-2, D-1",
        "D": "A-4, B-3, C-2, D-1"
      },
      "correct_answer": "D",
      "explanation": "Correct Answer: D) A-4, B-3, C-2, D-1 Explanation: Drugs with their respective targets of action: Trastuzumab HER2/neu Infliximab TNF alpha Sirolimus mTOR Imatinib BCR-ABL tyrosine kinase MOA Examples Uses Adverse effects HER2/neu Trastuzumab HER2-overexpressing breast and gastric cancer. Cardiotoxic, should be avoided with Doxorubicin TNF alpha Infliximab, Adalimumab, Certolizumab used to treat autoimmune conditions Increased risk of infections and cancer mTOR Sirolimus , Temsirolimus, Everolimus Medicated stents, Renal Cell Carcinoma, Breast Cancer, Pancreatic Neuroendocrine Tumors Mouth sores, rash, diarrhea, infections, elevated cholesterol, liver enzyme elevations, and lung issues. BCR-ABL tyrosine kinase Imatinib, Dasatinib, Nilotinib CML, Gastrointestinal Stromal Tumors (GIST) Generally well tolerated, some common side effects: Nausea and vomiting Fatigue and weakness Edema (swelling), particularly in the legs and ankles Muscle cramps and joint pain Rash and pruritus (itching) Reference: Goodman and Gilman’s Pharmacological Basis of Therapeutics, 14th Edition, Pages 1395,1388, 1390-1392, 1427, 1494, 1418-1419.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 3,
      "question": "In a patient diagnosed with breast cancer, who is 53 years old and also has heart failure, which medication should be avoided?",
      "options": {
        "A": "Methotrexate",
        "B": "Epirubicin",
        "C": "Cyclophosphamide",
        "D": "Cisplatin"
      },
      "correct_answer": "B",
      "explanation": "Correct Answer B - Epirubicin Epirubicin is an anthracycline chemotherapy agent known for its potential to cause cardiotoxicity, particularly in patients with pre-existing heart conditions like heart failure. This makes it contraindicated in such patients. Adverse effects of Epirubicin: Cardiomyopathy Alopecia Anemia Amenorrhea Leukopenia Diarrhea Methotrexate (Option A) is a folate antagonist used in cancer treatment, and it does not typically cause significant cardiotoxicity. It can have other side effects, but heart failure is not a contraindication for methotrexate use. Cyclophosphamide (Option C) is an alkylating agent used in breast cancer treatment. While it can have some cardiovascular effects, it is not as directly linked to severe cardiotoxicity as epirubicin. It is used cautiously but not avoided entirely in patients with heart failure. Cisplatin (Option D) is a platinum-based chemotherapy drug that primarily affects kidneys and has nephrotoxic potential. It does not carry the same level of risk for cardiotoxicity as epirubicin and can be used with caution in patients with heart failure, particularly if renal function is well monitored. Reference: Goodman and Gilman Pharmacological Basis of Therapeutics, 13th Edition Page 1192,1193",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 4,
      "question": "Nivolumab is used as a checkpoint inhibitor in which of the following?",
      "options": {
        "A": "Retinoblastoma",
        "B": "Medulloblastoma",
        "C": "Pleuropulmonaryblastoma",
        "D": "Hodgkin’s lymphoma"
      },
      "correct_answer": "D",
      "explanation": "Correct Answer D - Hodgkin’s lymphoma Nivolumab is a checkpoint inhibitor that targets the programmed cell death protein 1 (PD-1) receptor on T cells, which can help to overcome the tumour's ability to evade the immune system thu,s it is used in Hodgkin’s lymphoma. Nivolumab Nivolumab is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor on T cells. MOA PD-1 is a checkpoint protein that is expressed on the surface of T cells It helps to regulate the immune response by inhibiting T-cell activation and proliferation. It has two ligands, PD-L1 and PD-L2, and when PD-1 binds to these ligands, it sends a signal to the T cell to \"turn off\" and stop attacking the cancer cell. By blocking the PD-1 checkpoint, nivolumab enhances the anti-tumour activity of T cells and promotes an immune response against cancer cells. It is different from traditional chemotherapy and radiation therapy, and it is considered a type of immunotherapy that harnesses the immune system to fight cancer. Uses Replasped classical Hodgkin’s lymphoma Advanced melanoma Advanced non-small cell lung cancer (that was previously treated) Renal cell carcinoma Head and neck cancer Side effects Rash Fatigue, muscle pain Reduced appetite Constipation Pneumonitis Colitis Nephritis Hepatitis Reference: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 14th Edition, Page 1423",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 5,
      "question": "What is the mechanism of action of Methotrexate in Osteosarcoma?",
      "options": {
        "A": "Analogue of UMP",
        "B": "Competitive inhibitor of DHFR",
        "C": "Blocks Purine synthesis",
        "D": "Blocks Pyrimidine synthesis"
      },
      "correct_answer": "B",
      "explanation": "Correct Answer: B) Competitive inhibitor of DHFR Explanation: The anticancer action of methotrexate in osteosarcoma is achieved via competitive inhibition of dihydrofolate reductase (DHFR). Methotrexate is a folate analogue that inhibits dihydrofolate reductase and prevents the formation of Tetrahydrofolate, which is necessary for the synthesis of purine and pyrimidine. This results in decreased availability of nucleotides, and it disrupts DNA synthesis and cell proliferation. Folate Analogues\" data-author=\"\" data-hash=\"11924\" data-license=\"\" data-source=\"\" data-tags=\"May2025\" height=\"430\" src=\"https://image.prepladder.com/notes/ELqlyVYpU8PXG4lV3VbK1746441398.png\" width=\"560\" /> Uses of methotrexate Methotrexate Toxicity and Side Effects: Bone Marrow Suppression Megaloblastic anemia Alopecia and dermatitis Pneumonitis Nephrotoxicity (high doses) Defective oogenesis or spermatogenesis, abortion, and teratogenesis Hepatotoxic (Cirrhosis ) Intrathecal Administration of MTX can cause Meningismus Inflammatory Response in CSF Seizures, coma, and rare cases of death. Management of Methotrexate Toxicity: Stop methotrexate immediately. Administer leucovorin : It is advised to monitor methotrexate levels to establish the correct dosage and duration for leucovorin rescue therapy. Administer glucarpidase if serum methotrexate concentration is significantly elevated or persistent elevation with renal dysfunction. Hydration and alkalinization : IV fluids with sodium bicarbonate to alkalinize urine and promote methotrexate excretion. Hemodialysis Supportive Care: Blood transfusions, Antibiotics, Platelet transfusions",
      "image": null,
      "explanation_image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxpharmacology/Anticancer_Drugs-Previous_Year_Questions_Q5_exp.png",
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 6,
      "question": "Which of the following interleukin (IL) is inhibited by Tocilizumab?",
      "options": {
        "A": "IL-2",
        "B": "IL-5",
        "C": "IL-4",
        "D": "IL-6"
      },
      "correct_answer": "D",
      "explanation": "Correct Answer: D) IL-6 Explanation: Tocilizumab inhibits interleukin-6 (IL-6). It is a new humanized antibody that binds to soluble, membrane-bound IL-6 receptors and inhibits them, thus preventing IL-6-mediated signalling. IL-6 causes T-cell activation , acute phase protein synthesis and stimulation of inflammation and is involved in the pathogenesis of Rheumatoid arthritis, Giant cell arteritis and cytokine release syndrome. Uses Rheumatoid arthritis Juvenile Idiopathic arthritis Adverse effects Upper respiratory tract infections Hypertension Headache Deranged LFT IL-2 receptor (Option A) is inhibited by Daclizumab and Basiliximab, and they are used as immunosuppressive agents after renal and heart transplantation. IL-5 (Option B) is inhibited by Mepolizumab, Reslizumab, and Benralizumab, which can be used to reduce asthma exacerbations. IL-4 (Option D) is inhibited by Dupilumab, which can be used to reduce asthma exacerbations. Reference: Katzung’s Basic and Clinical Pharmacology, 14th Edition, Page 357, 653, 985 Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition, Page 638",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 7,
      "question": "A boy presents with pallor and lymphadenopathy, and an X-ray of his skull is given below. Which of the following drugs is not used for the management of the suspected diagnosis?",
      "options": {
        "A": "Cyclosporine",
        "B": "Methotrexate",
        "C": "Vinblastine",
        "D": "Vincristine"
      },
      "correct_answer": "D",
      "explanation": "Correct Answer D - Vincristine Based on the presentation of pallor, lymphadenopathy, and the X-ray showing punched-out and beveled lesions, LCH (Langerhans cell histiocytosis) is the possible diagnosis. While vincristine is used in the treatment of certain cancers, it is not typically used as a primary treatment for Langerhans cell histiocytosis. Skeletal and Radiological findings of LCH: Beveled-edge skull lesions (classic sign) Lytic bone lesions (especially in the skull, spine, and long bones) Button sequestra representing residual bone Geographic skull Mandible: Floating tooth (loss of lamina dura) Spine: Vertebra plana (M/c cause of vertebra plana in children) Reference: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 14th Edition, Page 1363,1364",
      "image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxpharmacology/Anticancer_Drugs-Previous_Year_Questions_Q7_q.jpg",
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 8,
      "question": "Which of the following is an inhibitor of DNA synthesis?",
      "options": {
        "A": "6-Mercaptopurine",
        "B": "Mitomycin",
        "C": "Actinomycin",
        "D": "Asparaginase"
      },
      "correct_answer": "A",
      "explanation": "Correct Answer: A) 6-Mercaptopurine Explanation: 6-mercaptopurine, also known as 6-MP, is an inhibitor of DNA synthesis. 6-MP is an antimetabolite that interferes with the synthesis of DNA by inhibiting the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT), which is involved in the synthesis of DNA and RNA. Mechanism of action: Uses: Acute lymphoblastic leukaemia (ALL) maintenance Inflammatory bowel disease (off-label) Mitomycin (Option B) is an alkylating agent that inhibits DNA synthesis by binding to DNA and cross-linking the DNA, preventing its replication. Actinomycin (Option C) inhibits DNA synthesis by causing single-stranded breaks in DNA, and it prevents its replication. Asparaginase (Option D) is an enzyme that depletes the amino acid asparagine. It does not directly inhibit DNA synthesis but affects protein synthesis by depleting asparagine, an essential amino acid for the growth of some cancer cells. Reference: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 14th Edition, Page 1360-1362",
      "image": null,
      "explanation_image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxpharmacology/Anticancer_Drugs-Previous_Year_Questions_Q8_exp.png",
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 9,
      "question": "A 40-year-old man was treated for a high-grade soft-tissue sarcoma with radiotherapy. Since he was not responding, he was shifted to chemotherapy. After initiating chemotherapy, he developed erythematous rashes over the areas where radiotherapy was administered earlier.Which of the following drugs causes this condition?",
      "options": {
        "A": "Vincristine",
        "B": "Doxorubicin",
        "C": "Cyclophosphamide",
        "D": "6-Mercaptopurine"
      },
      "correct_answer": "B",
      "explanation": "Correct Answer B - Doxorubicin Explanation: Doxorubicin is anthracycline chemotherapy which can lead to radiation recall dermatitis, which presents as erythematous rash in areas previously exposed to radiation therapy. This phenomenon occurs when Doxorubicin exacerbates or \"recalls\" the inflammatory reaction caused by prior radiation exposure. Doxorubicin MOA This leads to DNA Intercalation, Topoisomerase II Inhibition, and free radical formation, causing DNA damage. Uses Soft tissue sarcoma Hodgkins and Non-Hodgkins Lymphoma Lung carcinoma Leukaemia Side effects Radiation recall dermatitis Alopecia Stomatitis Dilated cardiomyopathy Peripheral neuropathy Hypersensitivity reaction - Rash and fever Hyperpigmentation of skin and nails Vincristine (Option A) is a vinca alkaloid chemotherapy drug that acts by disrupting the formation of microtubules in cells. It is not typically associated with radiation recall dermatitis. Cyclophosphamide (Option C) is an alkylating agent commonly used in chemotherapy. It is not known to cause radiation recall dermatitis. 6-mercaptopurine (Option D) is an antimetabolite chemotherapy drug used to treat various types of cancer. It does not typically cause radiation recall dermatitis. Reference: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 14th Edition, Page 1344, 1353, 1363 Anthracycline chemotherapy .",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 10,
      "question": "Which of the following is not an alkylating agent?",
      "options": {
        "A": "Melphalan",
        "B": "Cyclophosphamide",
        "C": "Busulfan",
        "D": "5-Fluorouracil"
      },
      "correct_answer": "D",
      "explanation": "Correct Answer: D) 5-Fluorouracil Explanation: 5-Fluorouracil (5-FU) is not an alkylating agent, and it is a fluoropyrimidine antimetabolite that interferes with DNA and RNA synthesis. 5-Fluorouracil MOA Inhibits thymidylate synthase after conversion to FdUMP, leading to decreased thymidine production and inhibition of DNA synthesis Uses Colorectal cancer FOLFOX Regimen : Folinic acid , Fluorouracil (5-FU), Oxaliplatin FOLFIRINOX Regimen : Folinic acid, Fluorouracil (5-FU), Irinotecan, Oxaliplatin All GIT cancer, along with platin Breast cancer Topical application on skin: For treatment of Mycosis Fungoides (Sezary Syndrome) Basal Cell Carcinoma Actinic Keratosis Side effects Bone marrow suppression Mucositis Hand-foot syndrome (palmar-plantar erythrodysesthesia) Alopecia Rarely - cardiotoxicity and neurotoxicity Melphalan (Option A) is an alkylating agent. It belongs to the class of nitrogen mustards and works by forming covalent bonds with DNA, leading to cross-linking and damage to the DNA strands which ultimately inhibits cell division and growth. Cyclophosphamide (Option B) is an alkylating agent. It is a prodrug that is metabolized in the body to its active form, phosphoramide mustard. Like other alkylating agents, cyclophosphamide forms covalent bonds with DNA, leading to DNA damage and disruption of cell division. Busulfan (Option C) is an alkylating agent. Busulfan works by forming DNA cross-links and inhibiting DNA synthesis, leading to the suppression of abnormal cell growth. Reference: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 14th Edition, Page 1356-1360",
      "image": null,
      "explanation_image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxpharmacology/Anticancer_Drugs-Previous_Year_Questions_Q10_exp.jpg",
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 11,
      "question": "Which monoclonal antibody is used in cancer treatment?",
      "options": {
        "A": "Omalizumab",
        "B": "Denosumab",
        "C": "Rituximab",
        "D": "Methotrexate"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) Rituximab Explanation: Rituximab is a monoclonal antibody used in the treatment of certain cancers, such as non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis. Rituximab A chimeric murine/human monoclonal IgG1 antibody targets the CD20 B-cell surface antigen. MOA Upon binding to CD20, it induces B-cell lysis through two main mechanisms: Complement-Dependent Cytotoxicity (CDC) and Antibody-Dependent Cellular Cytotoxicity (ADCC). Uses CD-20 positive B-cell non-Hodgkin's lymphoma Chronic lymphocytic leukemia Rheumatoid arthritis Pemphigus vulavaris Pharmacokinetics Half-life of 22 days Side effects Infusion reaction - fever, rash and joint pain Upper respiratory tract infections Steven johnson syndrome Thrombocytopenia HBV reactivation Tumor lysis syndrome Cytokine release syndrome Note Pretreatment with antihistamines, antipyretics and glucocorticoids reduces the risk of hypersensitivity reactions Incorrect Options: Omalizumab (Option A) is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE). It is used in Urticaria and Atopic Dermatitis. II Denosumab (Option B) is a fully human monoclonal antibody that binds the cytokine RANKL (receptor activator of NFKB ligand), an essential factor initiating bone turnover. RANKL inhibition blocks osteoclast maturation, function and survival, thus reducing bone resorption. II It is used for the treatment of Osteoporosis. Methotrexate (Option D) is an anti-metabolite, not a monoclonal antibody. It is most commonly used in chemotherapy and immunosuppressants in auto-immune diseases. Reference: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 14th Edition, Page 1418, 1420, 1435",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 12,
      "question": "Which adverse effect of Bleomycin is exacerbated by radiation exposure?",
      "options": {
        "A": "Pulmonary toxicity",
        "B": "Gastric toxicity",
        "C": "Neural toxicity",
        "D": "Hepatotoxicity"
      },
      "correct_answer": "A",
      "explanation": "significant adverse effect, and it is exacerbated by radiation exposure (a phenomenon known as radiation recall pneumonitis ). Mechanism: Bleomycin generates free radicals , leading to oxidative damage and fibrosis in the lungs. The lungs have low bleomycin hydrolase activity , making them more susceptible to damage. Radiation exposure further increases oxidative stress and inflammatory responses, worsening lung injury. Risk Factors: Cumulative bleomycin dose >400 units Concurrent oxygen therapy (risk of oxygen toxicity) Prior or concurrent radiation therapy Older age and renal impairment Clinical Features: Progressive dyspnoea, non-productive cough Interstitial pneumonitis → pulmonary fibrosis Restrictive lung disease with ↓ DLCO (diffusing capacity for carbon monoxide) Bleomycin is an antitumor antibiotic that is well-known for its association with pulmonary toxicity, including pulmonary fibrosis which occurs as follows: Gastric toxicity (Option B) is incorrect because bleomycin does not significantly affect the gastrointestinal tract . Neural toxicity (Option C) is incorrect because bleomycin does not cause neurotoxicity (unlike vincristine, which affects nerves). Hepatotoxicity (Option D) is incorrect because bleomycin has minimal liver toxicity compared to other chemotherapy agents. Reference: Goodman & Gillman’s pharmacological basis of Therapeutics, 14th edition, Page 1370",
      "image": null,
      "explanation_image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxpharmacology/Anticancer_Drugs-Previous_Year_Questions_Q12_exp.jpg",
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 13,
      "question": "What is basiliximab?",
      "options": {
        "A": "IL-1 receptor antagonist",
        "B": "Anit-CD3 antibody",
        "C": "IL-2 receptor antagonist",
        "D": "TNF inhibitor"
      },
      "correct_answer": "C",
      "explanation": "acts as an IL-2 receptor antagonist. It specifically binds to the alpha chain of the IL-2 receptor, which is expressed on activated T lymphocytes. By blocking this receptor, basiliximab inhibits IL-2 signaling and prevents T-cell activation and proliferation. It is primarily used as part of immunosuppressive therapy in kidney transplantation to reduce the risk of organ rejection. Incorrect Options: Option A: IL-1 receptor antagonist- IL-1 receptor antagonists are a class of drugs that specifically block the activity of interleukin-1 (IL-1), a pro-inflammatory cytokine. Basiliximab does not act as an IL-1 receptor antagonist. Option B: Anti-CD3 antibody- Anti-CD3 antibodies are monoclonal antibodies that target the CD3 antigen on T lymphocytes. They are used in certain immune-mediated disorders and organ transplantation to modulate T-cell function. Basiliximab is not an anti-CD3 antibody. Option D: TNF inhibitor- Tumor necrosis factor (TNF) inhibitors are a class of drugs that block the activity of TNF, a pro-inflammatory cytokine involved in various immune-mediated diseases. Basiliximab does not have TNF inhibitory properties.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 14,
      "question": "Which drug should not be administered to a pregnant woman?",
      "options": {
        "A": "Erythromycin",
        "B": "Amoxicillin",
        "C": "Ceftriaxone",
        "D": "Streptomycin"
      },
      "correct_answer": "D",
      "explanation": "harm to the developing fetus. Streptomycin is an antibiotic from the aminoglycoside class and has been associated with adverse effects on the fetal auditory and vestibular systems. It can cross the placenta and reach the developing fetus, potentially leading to hearing loss, balance problems, and other developmental abnormalities. Therefore, it is generally avoided during pregnancy unless the potential benefits outweigh the risks and no alternative treatment options are available. Incorrect Option: Option A) Erythromycin: Erythromycin is an antibiotic that is generally considered safe for use during pregnancy. It belongs to the macrolide class of antibiotics and has been widely used for the treatment of various infections in pregnant women without significant evidence of harm to the fetus. Option B) Amoxicillin: Amoxicillin is a commonly used antibiotic from the penicillin class and is generally considered safe for use during pregnancy. It has a long history of use in pregnant women with bacterial infections and has not been associated with significant risks to the fetus. Option C) Ceftriaxone: Ceftriaxone is a broad-spectrum antibiotic from the cephalosporin class. It is generally considered safe for use during pregnancy and is often prescribed for the treatment of various infections in pregnant women. Reference: ..",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 15,
      "question": "What is the mechanism of action of methyl dopa?",
      "options": {
        "A": "Blockade of beta adrenergic receptors",
        "B": "Agonism of beta 2 receptors",
        "C": "Agonism of alpha 2 receptors",
        "D": "Blockade of alpha 2 receptors"
      },
      "correct_answer": "C",
      "explanation": "of hypertension during pregnancy. Its mechanism of action involves agonism of alpha 2 adrenergic receptors. Methyldopa is converted in the body into methylnorepinephrine, which acts as a false neurotransmitter. Methylnorepinephrine stimulates alpha 2 receptors in the central nervous system (CNS), leading to a decrease in sympathetic outflow from the CNS. This ultimately results in reduced peripheral vascular resistance and lowered blood pressure. Incorrect Options: Option A) Blockade of beta adrenergic receptors: Methyldopa does not block beta adrenergic receptors. Beta blockers, on the other hand, are a separate class of antihypertensive medications that block beta adrenergic receptors to reduce blood pressure. Option B) Agonism of beta 2 receptors: Methyldopa does not directly agonize beta 2 receptors. Agonists of beta 2 receptors, such as albuterol, are commonly used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Option D) Blockade of alpha 2 receptors: Methyldopa does not block alpha 2 receptors. Blocking alpha 2 receptors would result in increased sympathetic outflow and potentially raise blood pressure. Medications that block alpha receptors, like alpha blockers, are used for different therapeutic purposes, such as the treatment of benign prostatic hyperplasia (BPH) or alpha-adrenergic antagonist poisoning.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 16,
      "question": "Which drug can be administered in the next cycle of chemotherapy to prevent neutropenia in a patient who has received anti-cancer therapy?",
      "options": {
        "A": "Filgrastim",
        "B": "Prednisolone",
        "C": "Vitamin B12",
        "D": "Folic acid"
      },
      "correct_answer": "A",
      "explanation": "prevent neutropenia in patients undergoing chemotherapy. Neutropenia is a condition characterized by a low level of neutrophils, a type of white blood cell that plays a crucial role in fighting off infections. Chemotherapy drugs can suppress the production of neutrophils, leading to an increased risk of infections. Filgrastim works by stimulating the production of neutrophils in the bone marrow, helping to prevent or reduce the severity and duration of neutropenia. By increasing the neutrophil count, it enhances the patient's ability to fight off infections. Incorrect Options : Option B. Prednisolone: Prednisolone is a corticosteroid that has anti-inflammatory and immunosuppressive effects. While it may be used in certain cases to manage inflammation or immune-related complications, it is not specifically indicated for the prevention of neutropenia. Option C . Vitamin B12: Vitamin B12 is a nutrient that plays a role in the production of red blood cells and the maintenance of nerve cells. While it is essential for overall health, it does not have a direct effect on preventing neutropenia. Option D . Folic acid: Folic acid is a B-vitamin that is important for the synthesis and repair of DNA and red blood cell production. Similar to vitamin B12, it does not have a direct effect on preventing neutropenia. Reference: ......",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 17,
      "question": "Which of the following medications must only be dispensed with a prescription from a licensed medical practitioner?",
      "options": {
        "A": "Schedule M drugs",
        "B": "Schedule H drugs",
        "C": "Schedule J Drugs",
        "D": "Schedule X drugs"
      },
      "correct_answer": "B",
      "explanation": "prescription from a registered medical practitioner. These drugs have a higher potential for misuse or abuse and may pose risks if used without proper medical supervision. Examples of Schedule H drugs include antibiotics, opioids, sedatives, and certain other prescription medications. Incorrect Options Option A. Schedule M drugs: Schedule M refers to drugs that are manufactured and marketed in India. These drugs are required to comply with Good Manufacturing Practices (GMP) guidelines. Schedule M does not specifically regulate the sale or prescription requirements of these drugs. However, it is important to note that the sale of all drugs, including Schedule M drugs, should comply with the applicable drug regulations and requirements, which may include prescription-only status for certain medications. Option C. Schedule J drugs: Schedule J refers to a category of drugs known as \"Strengthening Schedule J Drugs.\" These drugs are considered essential medicines for public health and are used to treat various diseases and conditions. The sale and prescription requirements for Schedule J drugs may vary depending on the specific drug and its formulation. Some Schedule J drugs may be available over-the-counter (OTC) or sold with certain restrictions, while others may require a prescription. Option D. Schedule X drugs: Schedule X drugs are a category of drugs that have a high potential for abuse and addiction. These drugs are tightly regulated and are subject to strict prescription and dispensing requirements. Schedule X drugs include narcotics, psychotropic substances, and certain other drugs that are considered dangerous and are controlled under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, of 1985. These drugs can only be prescribed and dispensed by registered medical practitioners with specific licenses.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 18,
      "question": "Which drug would you prioritize as the final treatment option for a patient who has developed glaucoma alongside diabetic macular edema?",
      "options": {
        "A": "Beta blocker",
        "B": "Alpha-blockers",
        "C": "Pilocarpine",
        "D": "Prostaglandin analogs"
      },
      "correct_answer": "D",
      "explanation": "considered the first-line treatment for glaucoma due to their effectiveness in significantly lowering IOP by increasing the outflow of aqueous humor through the uveoscleral pathway. They have a favorable side effect profile and are well tolerated. Additionally, prostaglandin analogs do not have significant systemic side effects and do not negatively impact diabetic macular edema. In fact, they may be beneficial as they do not affect the macular edema adversely, making them a suitable choice for patients with both conditions. Incorrect Options: Option A. Beta blockers: Beta blockers, such as timolol, are commonly used to lower intraocular pressure (IOP) in glaucoma patients. They work by reducing the production of aqueous humor. However, beta blockers can have systemic side effects, such as bronchospasm, bradycardia, and hypotension. They may also not be the best choice for a patient with diabetic macular edema (DME) because they don't address the macular edema directly. Option B. Alpha-blockers: Alpha agonists (not blockers), such as brimonidine, are used in glaucoma treatment to decrease aqueous humor production and increase uveoscleral outflow. While effective in reducing IOP, alpha agonists are not specifically beneficial for treating macular edema and can have side effects like ocular allergy and systemic hypotension. Option C. Pilocarpine: Pilocarpine is a cholinergic agent that works by increasing the outflow of aqueous humor through the trabecular meshwork, thus lowering IOP. However, it can cause side effects like miosis (constriction of the pupil) and ciliary spasm, which can reduce visual acuity, especially in patients with diabetic macular edema. It is generally less favored due to these side effects. Reference: ..",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 19,
      "question": "An infant had a serum bilirubin level of 33 mg/dL. The mother might have taken which of the following drugs during the third trimester for this to occur?",
      "options": {
        "A": "Ampicillin",
        "B": "Co-trimoxazole",
        "C": "Azithromycin",
        "D": "Chloramphenicol"
      },
      "correct_answer": "D",
      "explanation": "glucuronidation in the liver. By interfering with this metabolic pathway, chloramphenicol can increase serum bilirubin levels and potentially lead to neonatal hyperbilirubinemia. Therefore, if the mother took chloramphenicol during the third trimester, it could be a possible cause of the high serum bilirubin level in the infant. Incorrect Options: Option A . Ampicillin: Ampicillin is a broad-spectrum antibiotic commonly used during pregnancy to treat bacterial infections. It is not known to have a direct impact on bilirubin metabolism or cause significant changes in serum bilirubin levels. Therefore, it is unlikely to be the cause of the high serum bilirubin level in the infant. Option: B. Co-trimoxazole is a combination antibiotic used to treat various bacterial infections. Similar to ampicillin, co-trimoxazole is not known to directly affect bilirubin metabolism. It is therefore unlikely to be the cause of the high serum bilirubin level. Option C . Azithromycin: Azithromycin is an antibiotic commonly prescribed for respiratory tract infections and other bacterial infections. It has not been reported to have a direct impact on bilirubin metabolism. Therefore, it is unlikely to be the cause of the high serum bilirubin level.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 20,
      "question": "What is the term used to describe drugs that claim to contain a certain amount of a specific ingredient on their packaging, but actually have a lower amount in reality?",
      "options": {
        "A": "Misbranded drug",
        "B": "Adulterated drugs",
        "C": "Spurious drugs",
        "D": "Counterfeit drugs"
      },
      "correct_answer": "A",
      "explanation": "comply with the legal requirements or regulations set by the regulatory authorities. This could include inaccurate or misleading information on the label, improper instructions for use, or failure to meet labeling standards. Incorrect Options Option B . Adulterated drugs: Adulterated drugs are medications that have been tampered with or contaminated. They may contain impurities, substandard ingredients, or other substances that are not supposed to be present in the drug. Adulteration can occur during the manufacturing, packaging, or distribution process, compromising the quality and safety of the drug. Option C . Spurious drugs: Spurious drugs are counterfeit medications that are intentionally and fraudulently labeled with the name of a genuine drug, but they do not contain the correct active ingredients or may contain harmful substances. These drugs are intended to deceive consumers and may pose serious risks to health. Option D . Counterfeit drugs: Counterfeit drugs are medications that are intentionally and fraudulently produced or distributed with the intent to deceive. They may mimic the appearance, packaging, or labeling of genuine drugs, but they do not meet the quality standards or contain the correct active ingredients. Counterfeit drugs can be ineffective, unsafe, or even harmful to individuals who unknowingly use them. Reference: .",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 21,
      "question": "Which of the following teratogenic effects can be caused by the use of lithium during pregnancy?",
      "options": {
        "A": "Cardiac defects",
        "B": "Facial defects",
        "C": "CNS defects",
        "D": "Urogenital defects"
      },
      "correct_answer": "A",
      "explanation": "defects in the developing fetus. These defects may involve structural abnormalities of the heart, such as atrial and ventricular septal defects, as well as abnormalities in the heart's electrical conduction system. Incorrect Option Option B . Facial defects: Some studies have suggested a potential association between lithium use during pregnancy and an increased risk of facial defects in the fetus. These defects may include cleft lip or palate, although the evidence is not conclusive. Option C . CNS defects: Central nervous system (CNS) defects have also been reported in infants exposed to lithium in utero. These defects may include malformations of the brain and spinal cord, neural tube defects, and developmental delays. However, the specific risks and extent of these defects are still being studied. Option D . Urogenital defects: Lithium use during pregnancy has been associated with an increased risk of urogenital defects in the developing fetus. These defects may involve abnormalities in the urinary system, reproductive organs, or both. Reference: .",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 22,
      "question": "Which of the following drugs used in the treatment of breast cancer is a PARP inhibitor?",
      "options": {
        "A": "Rucaparib",
        "B": "Palbociclib",
        "C": "Vemurafenib",
        "D": "Gemcitabine"
      },
      "correct_answer": "A",
      "explanation": "Correct Answer: A) Rucaparib Explanation: Rucaparib is a PARP (Poly ADP-Ribose Polymerase) inhibitor used in the treatment of certain types of breast cancer, particularly those with BRCA mutations. Rucaparib: It is an oral PARP1–3 inhibitor approved in 2016 for advanced ovarian cancer with BRCA mutations, used in maintenance after platinum-based chemotherapy. It is also indicated for BRCA-mutated metastatic castration-resistant prostate cancer after endocrine and taxane therapy. It shares safety concerns with olaparib, including risks of MDS and AML . It is primarily metabolized by CYP2D6 and affects the metabolism of drugs like warfarin . The mean half-life is 25.9 hours. PARP inhibitors work by blocking the repair of DNA damage, leading to the death of cancer cells. Olaparib Rucaparib Niraparib Talazoparib Palbociclib (Option B) is a CDK4/6 inhibitor used in the treatment of HR-positive , HER2-negative breast cancer. It does not inhibit PARP and is not used as a PARP inhibitor. Vemurafenib (Option C) is a BRAF inhibitor , specifically targeting BRAF V600E mutations in cancers like melanoma . It does not affect PARP or its associated pathways. Gemcitabine (Option D) is a chemotherapy agent that inhibits DNA synthesis by interfering with nucleotides. It is not a PARP inhibitor and is used to treat various cancers like pancreatic cancer and non-small cell lung cancer . Reference: Goodman and Gilman's Pharmacological Basis of Therapeutics, 14th Edition, Pages 1403,1381",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 23,
      "question": "Aprepitant, a drug used to prevent late-onset chemotherapy-induced nausea and vomiting, acts through which of the following mechanisms?",
      "options": {
        "A": "NK-1 antagonist",
        "B": "NK-1 agonist",
        "C": "NK-3 antagonist",
        "D": "NK-2 antagonist"
      },
      "correct_answer": "A",
      "explanation": "the neurokinin-1 (NK-1) receptor. By blocking the NK-1 receptors, aprepitant inhibits the action of substance P, a neuropeptide involved in the emetic pathway. This helps to prevent nausea and vomiting, particularly the late-onset type associated with chemotherapy. Use: It is effective in managing delayed chemotherapy-induced nausea and vomiting (CINV) when used in combination with other antiemetic agents. Incorrect Options: Option B - NK-1 Agonist: This is incorrect because aprepitant is not an agonist but an antagonist of the NK-1 receptor. An NK-1 agonist would stimulate the receptor, potentially increasing the risk of nausea and vomiting rather than preventing it. Option C - NK-3 Antagonist: Aprepitant does not act on the NK-3 receptors. NK-3 receptors are another subtype of neurokinin receptors, and antagonists targeting these receptors are not used in the treatment of chemotherapy-induced nausea and vomiting. Option D - NK-2 Antagonist: Aprepitant is not an NK-2 antagonist. NK-2 receptors are another subtype involved in the emetic response, but aprepitant specifically targets the NK-1 receptors. NK-2 antagonists are not the primary agents used for preventing chemotherapy-induced nausea and vomiting.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 24,
      "question": "Which of the following drugs used in the treatment of Multiple Myeloma is associated with an increased risk of developing Herpes zoster infection?",
      "options": {
        "A": "Bortezomib",
        "B": "Daratumumab",
        "C": "Lomitapide",
        "D": "Lenalidomide"
      },
      "correct_answer": "A",
      "explanation": "the treatment of multiple myeloma and mantle cell lymphoma. Association with Herpes Zoster: Bortezomib has been associated with an increased risk of reactivation of the varicella-zoster virus (VZV), leading to Herpes zoster infection. This is due to the immunosuppressive effects of bortezomib, which can impair the immune system's ability to keep latent infections in check. Prophylaxis: Patients receiving bortezomib are often prescribed antiviral prophylaxis (e.g., acyclovir) to reduce the risk of Herpes zoster reactivation. Incorrect Options: Option B - Daratumumab: Mechanism of Action: Daratumumab is a monoclonal antibody that targets CD38 on plasma cells, used in the treatment of multiple myeloma. Infection Risk: While daratumumab is associated with an increased risk of respiratory infections due to its immunomodulatory effects, it is not specifically linked to a higher risk of Herpes zoster infection. Option C - Lomitapide: Mechanism of Action: Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used to treat homozygous familial hypercholesterolemia, not multiple myeloma. Relevance: Lomitapide is not associated with an increased risk of Herpes zoster, nor is it relevant in the context of multiple myeloma treatment. Option D - Lenalidomide: Mechanism of Action: Lenalidomide is an immunomodulatory drug used in multiple myeloma. Infection Risk: Although lenalidomide is associated with an increased risk of neutropenia and infections, it is not specifically associated with an increased risk of Herpes zoster infection compared to bortezomib.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 25,
      "question": "A 60-year-old patient undergoing treatment with Mycophenolate mofetil (MMF) presents with a serum calcium level of 13.5 mg/dL. He also has myasthenia gravis. What is the most likely cause of the hypercalcemia in this patient?",
      "options": {
        "A": "Drug-induced hypercalcemia",
        "B": "Primary hyperparathyroidism",
        "C": "Small cell lung cancer",
        "D": "Thymoma"
      },
      "correct_answer": "D",
      "explanation": "frequently associated with myasthenia gravis. Hypercalcemia can occur in patients with thymoma due to the production of parathyroid hormone-related peptide (PTHrP) by the tumor or associated paraneoplastic syndromes. Given the patient's history of myasthenia gravis, which is strongly associated with thymoma, the presence of hypercalcemia points to thymoma as the most likely cause. Incorrect Options: Option A - Drug-induced Hypercalcemia: Mycophenolate mofetil (MMF) is an immunosuppressant that is not typically associated with hypercalcemia. Drug-induced hypercalcemia is less likely in this scenario, particularly since MMF does not have hypercalcemia as a known side effect. Option B - Primary Hyperparathyroidism: Primary hyperparathyroidism is a common cause of hypercalcemia and would be a strong consideration in many patients. However, the association between myasthenia gravis and thymoma, along with the presence of hypercalcemia, makes thymoma a more likely diagnosis in this specific context. Option C - Small Cell Lung Cancer: Small cell lung cancer is more commonly associated with ectopic hormone production, such as ACTH or ADH, rather than PTHrP, which leads to hypercalcemia. Additionally, there is no direct link between myasthenia gravis and small cell lung cancer. Therefore, small cell lung cancer is an unlikely cause in this patient.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 26,
      "question": "Which of the following anti-cancer medications is used for the treatment of Gastrointestinal Stromal Tumors (GIST) and Chronic Myeloid Leukemia (CML)?",
      "options": {
        "A": "Imatinib",
        "B": "Methotrexate",
        "C": "Doxorubicin",
        "D": "Cisplatin"
      },
      "correct_answer": "A",
      "explanation": "Correct Answer: A) Imatinib Explanation: Imatinib is a drug of choice in the management of Chronic Myeloid Leukemia (CML) . CML is a myeloproliferative disorder characterized by the presence of the Philadelphia chromosome, resulting from a reciprocal translocation between chromosomes 9 and 22 [t(9;22)(q34;q11)], which generates the BCR-ABL fusion gene. This fusion gene encodes a constitutively active tyrosine kinase that drives the uncontrolled proliferation of myeloid cells. Imatinib binds to the ABL kinase portion of the BCR-ABL tyrosine kinase receptor, inhibiting its attachment and preventing cell division. By inhibiting this aberrant tyrosine kinase activity, imatinib selectively targets the underlying cause of CML, leading to inhibition of leukemic cell proliferation and induction of apoptosis. It is also used for the treatment of GIST (Gastrointestinal stromal tumors). Methotrexate (Option B) is a folate antimetabolite commonly used in the treatment of various cancers and autoimmune conditions. However, it is not used for GIST or CML. Doxorubicin (Option C) is an anthracycline antibiotic that is commonly used in the ABVD regimen for Hodgkin's lymphoma, but it is not specifically used for GIST or CML. Cisplatin (Option D) is a platinum-based chemotherapy drug used to treat cancers like testicular cancer, ovarian cancer, and lung cancer. It is not used for the treatment of GIST or CML. Reference: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 14th Edition, Page 1395",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 27,
      "question": "Which among the following is an HER-1 inhibitor?",
      "options": {
        "A": "Panitumumab",
        "B": "Crizotinib",
        "C": "Alectinib",
        "D": "Lorlatinib"
      },
      "correct_answer": "A",
      "explanation": "κ monoclonal antibody that binds to the extracellular domain III of the epidermal growth factor receptor (EGFR or HER-1). By binding to this receptor, panitumumab prevents ligand-dependent signaling, effectively inhibiting the EGFR pathway, which is often upregulated in certain types of cancer. Incorrect Options: Options B, C, and D are not inhibitors of EGFR or HER-1. They inhibit tyrosine kinase receptors. Option B - Crizotinib: Crizotinib is an orally bioavailable inhibitor of several receptor tyrosine kinases, including ROS1, HGFR/cMET, and ALK. It is Primarily used for non-small cell lung cancer (NSCLC) that is ALK-positive or ROS1-positive. Option C - Alectinib: Alectinib is also an orally bioavailable inhibitor of ALK kinase activity. It shows a higher selectivity for ALK than crizotinib and is active against mutant forms of ALK found in tumors resistant to crizotinib. Option D - Lorlatinib: Lorlatinib is a third-generation ALK inhibitor that targets ALK and ROS1.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 28,
      "question": "What is the primary mechanism of action of methotrexate?",
      "options": {
        "A": "Inhibits DNA synthesis by blocking thymidylate synthase",
        "B": "Inhibits dihydrofolate reductase, leading to decreased DNA synthesis",
        "C": "Inhibits RNA synthesis by blocking RNA polymerase",
        "D": "Interferes with microtubule formation during cell division"
      },
      "correct_answer": "B",
      "explanation": "Correct Answer: B) Inhibits dihydrofolate reductase, leading to decreased DNA synthesis reductase (DHFR). DHFR is responsible for converting dihydrofolate (DHF) into tetrahydrofolate (THF). THF is essential for the synthesis of purine nucleotides and thymidylate, which are crucial for DNA synthesis and repair. (Option A) By inhibiting DHFR, methotrexate decreases the production of THF, leading to a reduction in DNA synthesis. Inhibits RNA synthesis by blocking RNA polymerase (Option C): Methotrexate does not inhibit RNA polymerase directly. It primarily affects DNA synthesis by inhibiting DHFR. Interferes with microtubule formation during cell division (Option D): This mechanism is associated with drugs like taxanes and vinca alkaloids, which disrupt microtubule dynamics and mitosis. Methotrexate does not work through this mechanism. Reference: Goodman and Gilman Pharmacological Basis of Therapeutics,14th Edition, Page 1338.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 29,
      "question": "Which is true about the KEYNOTE 189 trial?",
      "options": {
        "A": "Pembrolizumab plus chemotherapy used in NSCLC",
        "B": "Nivolumab plus chemotherapy used in NSCLC",
        "C": "Pembrolizumab is used in NSCLC",
        "D": "Nivolumab is used in NSCLC"
      },
      "correct_answer": "A",
      "explanation": "Correct Answer A - Pembrolizumab plus chemotherapy used in NSCLC The patient's symptoms, CT findings, molecular testing, and biopsy tests of adenocarcinoma (the most common subtype of NSCLC) results are typical presentations for a patient with non-small cell lung carcinoma (NSCLC). Here, the patient has high PD-L1 expression (>50%). Pembrolizumab is particularly effective in NSCLC patients with high PD-L1 expression ( ≥ 50%) and is approved as a first-line treatment for these patients when there are no actionable mutations in EGFR, ALK, or ROS1. The KEYNOTE -189 trial investigated the use of pembrolizumab and chemotherapy in the treatment of non-small cell lung cancer (NSCLC). Conclusion of trial: In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a platinum-based drug resulted in significantly longer overall survival and progression-free survival than chemotherapy alone. Nivolumab plus chemotherapy used in NSCLC (Option B): The KEYNOTE-189 trial specifically focused on pembrolizumab and not nivolumab. Pembrolizumab is used in NSCLC (Option C): The KEYNOTE-189 trial investigated the combination of pembrolizumab with chemotherapy, not pembrolizumab alone, to treat NSCLC. The study had two treatment arms: one receiving pembrolizumab plus chemotherapy and the other receiving a placebo alongside chemotherapy. Nivolumab is used in NSCLC (Option D): The KEYNOTE-189 trial did not evaluate nivolumab for the treatment of NSCLC. Reference: Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer | New England Journal of Medicine https://clinicaltrials.gov/study/NCT02578680",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 30,
      "question": "A patient undergoing chemotherapy was given an antiemetic, after which he developed symptoms like acute dystonia, bradykinesia, and tremors . Which of the following drugs would have caused these symptoms?",
      "options": {
        "A": "Ondansetron",
        "B": "Metoclopramide",
        "C": "Meclizine",
        "D": "Scopolamine"
      },
      "correct_answer": "B",
      "explanation": "symptoms described in the given scenario. Metoclopramide is an antiemetic medication that is often used to treat nausea and vomiting associated with chemotherapy. It can cause acute dystonia (sudden, involuntary muscle contractions), bradykinesia (slowness of movement) and tremors. These symptoms are known as extrapyramidal side effects and are related to the drug's dopamine receptor antagonism in the brain. Incorrect Options: Option A - Ondansetron: Ondansetron works by blocking serotonin receptors, not dopamine receptors. Hence, extrapyramidal side effects are not seen. Option C - Meclizine: Meclizine is an antihistamine medication that is used to treat motion sickness and is not associated with extrapyramidal side effects. Option D - Scopolamine: Scopolamine is an anticholinergic medication. Hence, extrapyramidal side effects are not seen Reference: Prepladder Notes",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 31,
      "question": "What is the key difference between Cisplatin and Carboplatin?",
      "options": {
        "A": "Cisplatin is less neurotoxic than Carboplatin",
        "B": "Cisplatin causes fewer gastric issues compared to Carboplatin",
        "C": "Carboplatin is more neurotoxic than Cisplatin",
        "D": "Cisplatin has more nephrotoxic side effects compared to Carboplatin"
      },
      "correct_answer": "D",
      "explanation": "Cisplatin and Carboplatin are platinum-based chemotherapy agents, but Cisplatin is more nephrotoxic due to its accumulation in renal tubular cells. Key Differences: Cisplatin: More nephrotoxic → Causes acute tubular necrosis (ATN) and requires aggressive hydration with mannitol or amifostine to reduce damage. More neurotoxic and ototoxic → Causes peripheral neuropathy and sensorineural hearing loss (ototoxicity) . More severe nausea and vomiting . Carboplatin: Less nephrotoxic and does not require aggressive hydration. Less neurotoxic compared to cisplatin. More myelosuppressive (causes thrombocytopenia ). Cisplatin is known for its nephrotoxic effects, which can lead to acute kidney injury. The management of cisplatin-induced nephrotoxicity includes Adequate i.v. fluids - Chloride diuresis (Cl inactivates cisplatin) Mannitol - diuresis of inactivated cisplatin Use of nephroprotective agents like amifostine (only i.v.) Cisplatin is less neurotoxic than Carboplatin (Option A): Incorrect because Cisplatin is more neurotoxic (causing peripheral neuropathy ). Cisplatin causes fewer gastric issues compared to Carboplatin (Option B): Incorrect because Cisplatin causes more nausea and vomiting (highly emetogenic). Carboplatin is more neurotoxic than Cisplatin (Option C): Incorrect because Cisplatin is more neurotoxic than Carboplatin. Reference: Goodman & Gillman’s pharmacological basis of Therapeutics, 14th edition, Page 1352",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 32,
      "question": "Which of the following is the most common side effect induced by cisplatin chemotherapy?",
      "options": {
        "A": "GI symptoms",
        "B": "Neuropathy",
        "C": "Cardiotoxicity",
        "D": "Myopathy"
      },
      "correct_answer": "A",
      "explanation": "associated with cisplatin treatment. These symptoms may include nausea, vomiting, and loss of appetite. Cisplatin can irritate the stomach lining and trigger the body's vomiting reflex, leading to these discomforting GI effects. Incorrect Options: Option B - Neuropathy: Neuropathy, characterized by nerve damage and resulting in symptoms like numbness, tingling, and weakness, is a known side effect of cisplatin. However, it is not the most common side effect. Option C - Cardiotoxicity: While cisplatin can have cardiovascular side effects, such as abnormal heart rhythms and changes in blood pressure, cardiotoxicity is not typically the most common side effect of cisplatin. Option D - Myopathy: Myopathy refers to muscle-related side effects, including muscle weakness or pain. Although cisplatin can lead to myopathy, it is not the most common side effect. Reference: ....",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 33,
      "question": "In Carcinoma cervix, which chemotherapeutic agent is used?",
      "options": {
        "A": "Paclitaxel",
        "B": "Cyclophosphamide",
        "C": "Cisplatin",
        "D": "Topotecan"
      },
      "correct_answer": "C",
      "explanation": "used in the treatment of Carcinoma cervix, particularly in combination with other drugs or radiation therapy. It works by interfering with the DNA in cancer cells, preventing their growth and division. Cisplatin is often a key component in the treatment regimen for cervical cancer. Incorrect Options: Option A - Paclitaxel: Paclitaxel is a chemotherapy drug often used in the treatment of various cancers, including ovarian, breast, and lung cancers. While it may be used in combination with other drugs for certain gynecological cancers, it is not typically the primary chemotherapeutic agent used for Carcinoma cervix. Option B - Cyclophosphamide: Cyclophosphamide is a chemotherapy drug used to treat a variety of cancers, including some types of lymphoma and leukemia, as well as autoimmune disorders. It is not the primary chemotherapeutic agent used for Carcinoma cervix. Option D - Topotecan: Topotecan is a chemotherapy drug that is used in the treatment of various cancers, including ovarian and lung cancers. While it might be used in certain cases of recurrent or advanced cervical cancer, it is not typically the first-line chemotherapeutic agent of choice. Reference: .",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 34,
      "question": "Which of the following medications limit the accessibility of thymidylate?",
      "options": {
        "A": "Rituximab",
        "B": "Cisplatin",
        "C": "5-fluorouracil",
        "D": "Methotrexate"
      },
      "correct_answer": "C",
      "explanation": "is used in the treatment of various cancers, including colorectal cancer and breast cancer. It exerts its anticancer effects by inhibiting thymidylate synthase, an enzyme that plays a crucial role in the synthesis of thymidine, a building block of DNA. By inhibiting thymidylate synthase, 5-FU reduces the availability of thymidine, thereby interfering with DNA synthesis and inhibiting the growth of cancer cells. Incorrect Options: Option A - Rituximab: Rituximab is a monoclonal antibody used in the treatment of certain types of cancer, such as non-Hodgkin lymphoma, and autoimmune diseases like rheumatoid arthritis. It does not inhibit thymidylate synthesis. Option B - Cisplatin: Cisplatin is a chemotherapy drug used to treat various cancers, including testicular, ovarian, bladder, and lung cancer. It works by forming covalent bonds with DNA, causing cross-links and inhibiting DNA synthesis, but it does not directly inhibit thymidylate synthesis. Option D - Methotrexate: Methotrexate is an antimetabolite drug used in cancer chemotherapy and to treat autoimmune diseases like rheumatoid arthritis. It inhibits dihydrofolate reductase, which reduces the availability of tetrahydrofolate, an essential cofactor for thymidylate synthesis. However, it is not primarily known for restricting thymidylate availability.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 35,
      "question": "Which chemotherapeutic medication may lead to renal tubular damage in a patient?",
      "options": {
        "A": "Cisplatin",
        "B": "Streptozocin",
        "C": "Methysergide",
        "D": "Cyclophosphamide"
      },
      "correct_answer": "A",
      "explanation": "(kidney-damaging) effects. It is widely used in the treatment of various cancers, including testicular, ovarian, and bladder cancer. The nephrotoxicity of cisplatin is primarily due to its accumulation in the renal tubules, leading to cellular damage and impairment of renal function. Incorrect Options: Option B - Streptozocin: Streptozocin, is not typically associated with renal tubular damage. It is used in the treatment of pancreatic neuroendocrine tumors. Option C - Methysergide: Methysergide, is not a common chemotherapeutic medication. It is primarily used for the prevention of vascular headaches. Option D - Cyclophosphamide: Cyclophosphamide, can lead to hemorrhagic cystitis, but it is less commonly associated with renal tubular damage compared to Cisplatin.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 36,
      "question": "Osimertinib is used in NSCLC with mutation due to:",
      "options": {
        "A": "ROS1 mutation",
        "B": "T890M mutation",
        "C": "T790M mutation",
        "D": "M790T mutation"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) T790M mutation Osimertinib is used in NSCLC (non-small cell lung cancer) with T790M mutation. It is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) primarily used in NSCLC (non-small cell lung cancer). It is specifically effective against NSCLC that harbours the T790M mutation in the EGFR gene. The T790M mutation is commonly associated with resistance to first-generation EGFR TKIs like gefitinib and erlotinib. Osimertinib works by selectively inhibiting mutant forms of EGFR, including those with the T790M mutation while sparing wild-type EGFR, which helps reduce toxicity. Clinical trials have demonstrated the efficacy of osimertinib in patients with NSCLC who have developed resistance to previous EGFR TKIs due to the T790M mutation. ROS1 mutation (Option A): Osimertinib is not indicated for NSCLC with ROS1 mutations. ROS1 rearrangements are a distinct molecular subtype of NSCLC and targeted therapies like crizotinib, ceritinib, and entrectinib are more commonly used in this case. T890M mutation (Option B): There is no known mutation referred to as T890M. The correct mutation associated with osimertinib efficacy is T790M. M790T mutation (Option D): Similarly, there is no known mutation termed M790T. The correct mutation is T790M. Reference: Goodman and Gilman’s Pharmacological Basis of Therapeutics, 14th Edition, Page 1408.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 37,
      "question": "What is the treatment for HER-2-positive trastuzumab-resistant breast cancer?",
      "options": {
        "A": "Lapatinib",
        "B": "Sorafenib",
        "C": "Vemurafenib",
        "D": "Erlotinib"
      },
      "correct_answer": "A",
      "explanation": "Correct Answer: A) Lapatinib Lapatinib is given in cases of trastuzumab-resistant HER-2 positive breast cancer. It is an oral tyrosine kinase inhibitor that targets both HER-2 and EGFR (epidermal growth factor receptor). It is approved for the treatment of HER-2 positive breast cancer, either as monotherapy or in combination with trastuzumab. Mutation Target Drug Generation/Type Explanation HER1 (EGFR) - Non-Small Cell Lung Cancer Erlotinib , Gefitinib (Option D) 1st Generation Given in EGFR (+)ve lung cancer, pancreatic cancer. Afatinib, Dacomitinib 2nd Generation Given in resistance of Erlotinib & Gefitinib. Osimertinib 3rd Generation Given in resistant cases of Afatinib & Dacomitinib. Given in T790M mutation in EGFR receptor. Mobocertinib 4th Generation Given in resistant cases of Osimertinib. Cetuximab, Panitumumab, Necitumumab MAB Approved Blocks EGFR. HER2+ve - Breast Cancer Lapatinib Given in Trastuzumab-resistant cases. Neratinib, Tucatinib Used in HER2 (+)ve breast cancer. Sorafenib (Option B) is a multi-kinase inhibitor primarily used for the treatment of advanced kidney cancer and liver cancer. While it has shown activity against various kinases involved in tumor growth and angiogenesis, it is not a standard treatment for trastuzumab-resistant breast cancer. Vemurafenib (Option C) is a targeted therapy used for the treatment of metastatic melanoma with a specific mutation (BRAF V600E). It is not indicated or effective in the treatment of HER-2 positive breast cancer. Reference: Goodman & Gilman Pharmacological Basis of Therapeutics, 14th Edition, Page 1384-1386 and1408",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 38,
      "question": "Which of the following is the most common side effect induced by cisplatin chemotherapy?",
      "options": {
        "A": "GI symptoms",
        "B": "Neuropathy",
        "C": "Cardiotoxicity",
        "D": "Myopathy"
      },
      "correct_answer": "A",
      "explanation": "Correct Answer A - GI symptoms Gastrointestinal (GI) symptoms are the most common side effects associated with Cisplatin (platinum-containing chemotherapy drug) treatment, including symptoms like nausea, vomiting, and loss of appetite. Mechanism of action: It works by interfering with the DNA in cancer cells, preventing their growth and division. Uses: It is widely used in the treatment of various cancers, including testicular, ovarian, bladder cancer, and carcinoma cervix (in combination with other drugs or radiation therapy). Adverse Effects: Nephrotoxicity Ototoxicity GI symptoms (nausea, vomiting) Progressive peripheral motor and sensory neuropathy Myelosuppression (leukopenia, thrombocytopenia, anemia Electrolyte disturbances (hypomagnesemia, hypocalcemia, hypokalemia, and hypophosphatemia) Hyperuricemia, hemolytic anemia, and cardiac abnormalities are rare side effects. Anaphylactic-like reactions (facial edema, bronchoconstriction, tachycardia, and hypotension). Neuropathy (Option B) is characterised by nerve damage and resulting in symptoms like numbness, tingling, and weakness, which is a known side effect of cisplatin. However, it is not the most common side effect. Cardiotoxicity (Option C): While cisplatin can have cardiovascular side effects, such as abnormal heart rhythms and changes in blood pressure, cardiotoxicity is not typically the most common side effect of cisplatin. Myopathy (Option D) refers to muscle-related side effects, including muscle weakness or pain. Although cisplatin can lead to myopathy, it is not the most common side effect.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 39,
      "question": "Which of the following drugs are used to treat chemotherapy-induced nausea and vomiting?",
      "options": {
        "A": "Doxylamine + domperidone + aprepitant",
        "B": "Prochlorperazine + metoclopramide + domperidone",
        "C": "Dexamethasone + metoclopramide + domperidone",
        "D": "Granisteron + dexamethasone + aprepitant"
      },
      "correct_answer": "D",
      "explanation": "Correct Answer D - Granisteron + dexamethasone + aprepitant Chemotherapy can trigger the release of chemicals like serotonin and substance P, which activate the vomiting centre in the brain, and this can be treated with a combination of granisetron + dexamethasone + aprepitant. First-line therapies (include any of or a combination of) Drugs Mechanism of Action Granisetron or Ondansetron They are 5-HT3 receptor antagonist , which blocks receptors in the gut and brain stimulated by serotonin released during chemotherapy, reducing nausea and preventing vomiting. Dexamethasone A corticosteroid with anti-inflammatory and immunosuppressive effects, it reduces gastrointestinal inflammation and suppresses the release of chemicals in the brain that trigger nausea and vomiting. Aprepitant It is a substance P/neurokinin 1 (NK1) receptor antagonist that works by blocking NK1 receptors, inhibiting the action of substance P (a neurotransmitter involved in triggering nausea and vomiting). This medication is often used in combination with others as it targets different pathways in the development of chemotherapy-induced nausea and vomiting (CINV), offering a more comprehensive approach to prevention and management. This combination therapy is particularly effective in preventing both acute and delayed CINV. Doxylamine + domperidone + aprepitant (Option A): Doxylamine is primarily an antihistamine used for morning sickness in pregnant women and is not commonly used to treat chemotherapy-induced nausea and vomiting. Domperidone is a medication used to treat nausea and vomiting but is not the first-line treatment for chemotherapy-induced nausea and vomiting. Prochlorperazine + metoclopramide + domperidone (Option B): Prochlorperazine is an antipsychotic medication used to treat schizophrenia and other psychiatric disorders. While it can be used to treat nausea and vomiting, it is not a first-line treatment for chemotherapy-induced nausea and vomiting. Dexamethasone + metoclopramide + domperidone (Option C): Dexamethasone and metoclopramide can be used to treat chemotherapy-induced nausea and vomiting; they are not first-line treatments. Additionally, the addition of domperidone is not typically recommended for the treatment of chemotherapy-induced nausea and vomiting. Reference: Goodman and Gilman’s Pharmacological Basis of Therapeutics, 14th Edition, Page 1099-1104.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 40,
      "question": "The active metabolite of cyclophosphamide is :",
      "options": {
        "A": "Aldophosphamide",
        "B": "4- hydroxy cyclophosphamide",
        "C": "4-Ketocyclophosphamide",
        "D": "Carboxyphosphamide"
      },
      "correct_answer": "B",
      "explanation": "chemotherapy drug that requires metabolism in the liver by CYP2B6 to form its active metabolite. 4-hydroxy cyclophosphamide can then spontaneously decompose to form aldophosphamide , which is ultimately converted into phosphoramide mustard, a highly reactive compound that causes DNA crosslinking and kills rapidly dividing cells, which is the mechanism by which cyclophosphamide exerts its anti-cancer effect. Hemorrhagic cystitis is a known adverse effect of cyclophosphamide. It occurs when acrolein, a toxic metabolite, forms, irritating the bladder mucosa and causing hemorrhage. Aldophosphamide (Option A) is an intermediate metabolite but not the primary active metabolite. It is formed from 4-hydroxy cyclophosphamide. Aldophosphamide undergoes spontaneous breakdown to form phosphoramide mustard, which is the ultimate active cytotoxic agent. 4-Ketocyclophosphamide (Option C) is an inactive metabolite formed by oxidation of 4-hydroxy cyclophosphamide. Carboxyphosphamide (Option D) is also an inactive metabolite , formed by oxidation of cyclophosphamide. It is a non-toxic metabolite and has no role in the drug's cytotoxic effects. Reference: Goodman and Gilman Pharmacological Basis of Therapeutics,14th Edition, Page 1346",
      "image": null,
      "explanation_image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxpharmacology/Anticancer_Drugs-Previous_Year_Questions_Q40_exp.jpg",
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 41,
      "question": "Which among the following drugs is the new FDA-approved immune checkpoint inhibitor for carcinoma endometrium?",
      "options": {
        "A": "Nivolumab",
        "B": "Pembrolizumab",
        "C": "Ipilimumab",
        "D": "Trastuzumab"
      },
      "correct_answer": "B",
      "explanation": "receptor on T cells. It is a type of immunotherapy known as an immune checkpoint inhibitor, which works by blocking the PD-1 receptor, thereby enabling the immune system to recognize and attack cancer cells. It was approved by the FDA in 2019 for the treatment of advanced or recurrent endometrial cancer that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). Nivolumab (Option A) & Ipilimumab (Option C): They both are other immune checkpoint inhibitors that the FDA has approved for the treatment of various types of cancer, including melanoma and lung cancer , but they have not been specifically approved for the treatment of endometrial cancer. Trastuzumab (Option D) is a HER2-targeted therapy (monoclonal antibody) used in HER2-positive breast cancer and gastric cancer, but it is not relevant for endometrial carcinoma. Reference: Goodman & Gillman’s Pharmacological Basis of Therapeutics, 14th Edition, Pages 1422, 1385,1420,1423 FDA Link",
      "image": null,
      "explanation_image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxpharmacology/Anticancer_Drugs-Previous_Year_Questions_Q41_exp.jpg",
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 42,
      "question": "The Nobel Prize in Physiology or Medicine , 2018 was awarded to James P. Allison and Tasuku Honjo for which of the following discoveries?",
      "options": {
        "A": "Discovery of mechanisms of autophagy",
        "B": "Discoveries of molecular mechanisms controlling the circadian rhythm",
        "C": "Discovery of cancer therapy by inhibition of negative immune regulation",
        "D": "The discovery that matures cells can be reprogrammed to become pluripotent"
      },
      "correct_answer": "C",
      "explanation": "Discovery of cancer therapy by inhibition of negative immune regulation: The Nobel Prize in Physiology or Medicine, 2018 was awarded to James P. Allison and Tasuku Honjo for their discovery of cancer therapy by inhibition of negative immune regulation. Their work led to the development of immune checkpoint inhibitors, which are drugs that can block the interaction between checkpoint proteins and their receptors, unleashing the immune system's ability to attack cancer cells. Incorrect Options: Option A - Discovery of mechanisms of autophagy: The Nobel Prize in Physiology or Medicine, 2016 was awarded to Yoshinori Ohsumi for his discoveries of mechanisms of autophagy. Option B - Discoveries of molecular mechanisms controlling the circadian rhythm: The Nobel Prize in Physiology or Medicine, 2017 was awarded to Jeffrey C. Hall, Michael Rosbash, and Michael W. Young for their discoveries of molecular mechanisms controlling the circadian rhythm. Option D - Discovery that mature cells can be reprogrammed to become pluripotent : The Nobel Prize in Physiology or Medicine, 2012 was awarded to Sir John B. Gurdon and Shinya Yamanaka for their discovery that mature cells can be reprogrammed to become pluripotent. Reference: Prepladder Notes",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 43,
      "question": "Which of the following drugs causes flagellate pigmentation ?",
      "options": {
        "A": "Bleomycin",
        "B": "Doxorubicin",
        "C": "Vincristine",
        "D": "Minocycline"
      },
      "correct_answer": "A",
      "explanation": "various malignancies, including lymphomas, testicular cancer, and squamous cell carcinomas. One of the known side effects of Bleomycin is flagellate pigmentation, which refers to a distinctive linear pattern of pigmentation resembling whip-like streaks on the skin. It is an uncommon side effect but can occur with prolonged use of the drug. Incorrect Options: Option B - Doxorubicin: Doxorubicin is an anthracycline chemotherapy drug used to treat various types of cancer, including breast cancer, lung cancer, and leukemia. While doxorubicin can cause various side effects, including hair loss and discoloration of nails, it is not associated with flagellate pigmentation. Option C - Vincristine: Vincristine is a chemotherapy drug commonly used in the treatment of leukemia, lymphoma, and solid tumors. It is not known to cause flagellate pigmentation. However, vincristine can cause other side effects, such as peripheral neuropathy, constipation, and hair loss. Option D - Minocycline: Minocycline is an antibiotic in the tetracycline class, commonly used to treat bacterial infections, including acne. Prolonged use of minocycline has been associated with a side effect known as minocycline-induced pigmentation. This pigmentation can be present in various types, including blue-gray pigmentation of the skin, mucous membranes, and nails. However, it does not specifically cause flagellate pigmentation. Reference: Prepladder Notes",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 44,
      "question": "Which is the anticoagulant of choice for the management of cancer–associated thromboembolism ?",
      "options": {
        "A": "Unfractionated Heparin",
        "B": "Warfarin",
        "C": "Low molecular weight heparin",
        "D": "Dabigatran"
      },
      "correct_answer": "C",
      "explanation": "but has a smaller molecular size, which allows for more predictable anticoagulant effects and longer half-life. LMWH, such as enoxaparin or dalteparin, is typically administered subcutaneously once or twice daily and does not require routine monitoring. It has demonstrated efficacy and safety in preventing and treating venous thromboembolism in cancer patients and is considered the anticoagulant of choice in this population. Incorrect Options: Option A - Unfractionated Heparin : Unfractionated Heparin UFH requires continuous intravenous infusion or subcutaneous injections and necessitates monitoring of the activated partial thromboplastin time (aPTT) to adjust the dose. While UFH can be used in cancer-associated thromboembolism, it is generally less preferred compared to low molecular weight heparin (LMWH) due to the need for frequent monitoring and a higher risk of heparin-induced thrombocytopenia. Option B - Warfarin : Warfarin is an oral vitamin K antagonist that inhibits the production of clotting factors in the liver. It requires regular monitoring of the international normalized ratio (INR) to maintain the desired level of anticoagulation. While warfarin is commonly used for long-term anticoagulation in various conditions, its use in cancer-associated thromboembolism is limited due to drug interactions, variable response, and the need for careful dose adjustment. Additionally, cancer patients may have an increased bleeding risk, which can complicate the use of warfarin. Option D - Dabigatran : Dabigatran is a direct oral anticoagulant (DOAC) that directly inhibits thrombin, a key enzyme in the blood clotting process. While DOACs have gained popularity in various clinical settings, including non-valvular atrial fibrillation and venous thromboembolism, their use in cancer-associated thromboembolism is limited. The evidence for DOACs in this specific population is limited, and they may have interactions with certain cancer treatments. Reference: Prepladder Notes",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 45,
      "question": "Which of the following anti-CD 20 monoclonal antibodies is used in cancer therapy?",
      "options": {
        "A": "Methotrexate",
        "B": "Rituximab",
        "C": "Cisplatin",
        "D": "5-Fluorouracil"
      },
      "correct_answer": "B",
      "explanation": "treatments. It blocks the CD20 receptor, which is a marker of B-lymphocyte. Incorrect options: Option A. Methotrexate is an antimetabolite. It is also a chemotherapy agent and immune suppressant. Option C. Cisplatin is an antineoplastic agent. Option D. 5-Fluorouracil is a cytotoxic drug. Reference: Prer Ladder notes and NIH",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 46,
      "question": "Monoclonal antibody used in cancer ?",
      "options": {
        "A": "Rituximab",
        "B": "Cisplatin",
        "C": "5-Fluorouracil",
        "D": "Methotrexate"
      },
      "correct_answer": "A",
      "explanation": "types of cancer. It specifically targets and binds to a protein called CD20, which is found on the surface of B-lymphocytes. Rituximab works by promoting the destruction of cancerous B-cells and modulating the immune response against cancer. Rituximab is primarily used in the treatment of B-cell non-Hodgkin lymphoma (NHL), including follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia (CLL). It is also utilized in the management of certain autoimmune disorders, such as rheumatoid arthritis and pemphigus vulgaris. Incorrect Options: Option B - Cisplatin: Cisplatin is a platinum-based chemotherapy drug that is not a monoclonal antibody. It works by damaging the DNA in cancer cells, leading to their death. Option C - 5-Fluorouracil: 5-Fluorouracil is a chemotherapy drug that inhibits the synthesis of DNA and RNA, leading to the destruction of cancer cells. It is not a monoclonal antibody. Option D - Methotrexate: Methotrexate is a chemotherapy drug that interferes with DNA synthesis and cell division. It is used in the treatment of various cancers, as well as autoimmune conditions. However, it is not a monoclonal antibody. Reference: Prepladder Notes",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 47,
      "question": "Which is most cardiotoxic anticancer drug ?",
      "options": {
        "A": "Anthracyclines",
        "B": "Cyclophosphamide",
        "C": "Tamoxifen",
        "D": "Imatinib"
      },
      "correct_answer": "A",
      "explanation": "idarubicin, and mitoxantrone are other anthracycline analogs. Doxorubicin's cardiotoxicity is primarily associated with its potential to cause damage to the heart muscle, leading to a condition called cardiomyopathy. It can result in symptoms such as shortness of breath, fatigue, chest pain, and fluid retention. Incorrect Options: Option B - Cyclophosphamide: Cyclophosphamide belongs to alkylating agents Option C - Tamoxifen: Tamoxifen is a selective estrogen receptor modulator Option D - Imatinib: Imatinib is a tyrosine kinase inhibitor. All these drugs are less cardiotoxic than anthracyclines. Reference: Prepladder Notes",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    },
    {
      "q_no": 48,
      "question": "Which of the following drugs is associated with untoward side effects of renal tubular damage ?",
      "options": {
        "A": "Cisplatin",
        "B": "Streptozocin",
        "C": "Methysergide",
        "D": "Cyclophosphamide"
      },
      "correct_answer": "A",
      "explanation": "including testicular, ovarian, bladder, and lung cancers. Renal tubular damage is a well-known side effect of cisplatin. Cisplatin is taken up by the proximal tubular cells in the kidney, where it accumulates and causes the tubular cells' oxidative stress, inflammation, and apoptosis. This can lead to acute kidney injury, electrolyte imbalances, and chronic kidney disease. Incorrect Options: Option B - Streptozocin : Streptozocin is an alkylating agent used to treat pancreatic islet cell carcinoma. It causes diabetes mellitus due to destruction of beta cells of pancreas. It can cause kidney damage, but this is typically due to its effects on the glomerulus rather than the renal tubules. Option C - Methysergide: Methysergide is a serotonin antagonist that is used to treat migraines. It is associated with retroperitoneal fibrosis not renal tubular damage. Option D - Cyclophosphamide: Cyclophosphamide is an alkylating agent that is used to treat a variety of cancers and autoimmune diseases. It causes hemorrhagic cystitis. Reference: Prepladder Notes",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Previous Year Questions"
    }
  ]
}
